Who Paid My Doc
Phase II study in SCLC and epNEC
Research payments
$3,897,064
Through program year 2025, $3,897,064 in research payments was reported against Phase II study in SCLC and epNEC, across 63 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $30,855 | 10 |
| 2024 | Research | $3,821,920 | 39 |
| 2023 | Research | $44,289 | 14 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Thorvardur Halfdanarson Rochester, MN Named on 5 payments
- Jason Starr Jacksonville, FL Named on 4 payments
- Bridget Keenan San Francisco, CA Named on 3 payments
- Aman Chauhan Miami, FL Named on 3 payments
- Jonathan Strosberg Tampa, FL Named on 3 payments
- Mohamad Sonbol Scottsdale, AZ Named on 3 payments
- David Berz Los Angeles, CA Named on 3 payments
- Chao Huang Kansas City, KS Named on 3 payments
- Taofeek Owonikoko Pittsburgh, PA Named on 3 payments
- Sally Lau New York, NY Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.